Advertisement
U.S. markets close in 29 minutes
  • S&P 500

    5,262.73
    +14.24 (+0.27%)
     
  • Dow 30

    39,855.16
    +95.08 (+0.24%)
     
  • Nasdaq

    16,398.78
    -0.74 (-0.00%)
     
  • Russell 2000

    2,124.26
    +9.91 (+0.47%)
     
  • Crude Oil

    83.10
    +1.75 (+2.15%)
     
  • Gold

    2,241.50
    +28.80 (+1.30%)
     
  • Silver

    24.97
    +0.21 (+0.86%)
     
  • EUR/USD

    1.0792
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0015 (-0.11%)
     
  • USD/JPY

    151.4030
    +0.1570 (+0.10%)
     
  • Bitcoin USD

    70,721.09
    +2,047.45 (+2.98%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Best Biotech ETFs Gets a Lift From Merck’s Cubist Buy

Shares of biotechnology firm Cubist Pharmaceuticals (CBST) are up more than 35% Monday after Dow component Merck (MRK) said it will buy the company for $102 per share, a deal that values Cubist at $9.5 billion.

News of the deal lifted the First Trust NYSE Arca Biotechnology Index Fund (FBT) to another all-time high. Already this year’s top-performing non-leveraged sector exchange traded fund with a gain of 52.4%, FBT entered Monday with a 3.3% weight to Cubist, the largest among the five major non-leveraged biotech ETFs.

Last week, it was reported that FBT stood to benefit from news coming out of Cubist’s December 21 Prescription Drug User Fee Act (PDUFA) date where the company is seeking Food & Drug Administration approval for its treatment of urinary tract and intra-abdominal infections. [December Could be a Big Month for Biotech ETFs]

This is not the first time this year that the $2 billion FBT has benefited from biotech mergers and acquisitions activity. The ETF held an almost 6% weight to InterMune (ITMN), making the stock the ETF’s largest holding, in late August when Swiss pharmaceuticals giant Roche announced Sunday it would acquire InterMune for $8.3 billion in cash. [InterMune Deal Could Boost These Biotech ETFs]

Nor is this the first time this year a biotech acquisition courtesy of Merck has lifted biotech ETFs. The PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) surged in June when Merck said it would acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion.

The SPDR S&P Biotech ETF (XBI) , which is an equal-weight ETF, entered Monday with a weight to Cubist Pharmaceuticals of 1.25%. That is enough to have XBI higher by 2.3% on volume that has already eclipsed the trailing three-month daily average. Like FBT, XBI also touched an all-time earlier today.

Up 42.4% year-to-date, XBI is 2014’s second-best sector ETF behind FBT.

First Trust NYSE Arca Biotechnology Index Fund

fbt
fbt

ETF Trends editorial team contributed to this post.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Advertisement